Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691–705

Article  PubMed  PubMed Central  Google Scholar 

Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497

Article  CAS  PubMed  Google Scholar 

Kim J, Combs K, Downs J, Tillman F III (2018) Medication adherence: the elephant in the room. US Pharmacist 43:30–34

Google Scholar 

De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, Vrijens B (2018) ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med 169(1):30–35

Article  PubMed  PubMed Central  Google Scholar 

Lowy A, Munk VC, Ong SH, Burnier M, Vrijens B, Tousset EP, Urquhart J (2011) Effects on blood pressure and cardiovascular risk of variations in patients’ adherence to prescribed antihypertensive drugs: role of duration of drug action. Int J Clin Pract 65(1):41–53

Article  CAS  PubMed  Google Scholar 

Stauffer ME, Hutson P, Kaufman AS, Morrison A (2017) The adherence rate threshold is drug specific. Drugs R &D 17(4):645–653

Article  CAS  Google Scholar 

Assawasuwannakit P, Braund R, Duffull SB (2015) Quantification of the forgiveness of drugs to imperfect adherence. CPT 4(3):204–211

Google Scholar 

Assawasuwannakit P, Braund R, Duffull SB (2016) A framework for quantifying the influence of adherence and dose individualization. Clin Pharmacol Ther 99(4):452–459

Article  CAS  PubMed  Google Scholar 

Boissel J-P, Nony P (2002) Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin Pharmacokinet 41(1):1–6

Article  CAS  PubMed  Google Scholar 

Garnett WR, McLean AM, Zhang Y, Clausen S, Tulloch SJ (2003) Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. Curr Med Res Opin 19(6):519–525

Article  CAS  PubMed  Google Scholar 

Reed RC, Dutta S (2004) Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium. Am J Health Syst Pharm 61(21):2284–2289

Article  CAS  PubMed  Google Scholar 

Dutta S, Reed RC (2006) Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician 1. J Clin Pharm Ther 31(4):321–329

Article  CAS  PubMed  Google Scholar 

Ding J, Zhang Y, Jiao Z, Wang Y (2012) The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using monte carlo simulation. Acta Pharmacol Sin 33(11):1431–1440

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen C, Wright J, Gidal B, Messenheimer J (2013) Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation. Ther Drug Monit 35(2):188–193

Article  CAS  PubMed  Google Scholar 

Gidal BE, Majid O, Ferry J, Hussein Z, Yang H, Zhu J, Fain R, Laurenza A (2014) The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies. Epilepsy Behav 35:6–12

Article  PubMed  Google Scholar 

Brittain ST, Wheless JW (2015) Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations. Epilepsy Behav 52:31–36

Article  PubMed  Google Scholar 

Sunkaraneni S, Blum D, Ludwig E, Chudasama V, Fiedler-Kelly J, Marvanova M, Bainbridge J, Phillips L (2018) Population pharmacokinetic evaluation and missed-dose simulations for eslicarbazepine acetate monotherapy in patients with partial-onset seizures. Clin Pharmacol Drug Dev 7(3):287–297

Article  CAS  PubMed  Google Scholar 

Hard ML, Wehr AY, Sadler BM, Mills RJ, von Moltke L (2018) Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. Eur J Drug Metab Pharmacokinet 43(4):461–469

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elkomy MH (2020) Changing the drug delivery system: does it add to non-compliance ramifications control? A simulation study on the pharmacokinetics and pharmacodynamics of atypical antipsychotic drug. Pharmaceutics 12(4):297

Article  PubMed  PubMed Central  Google Scholar 

Jia-qin G, Guo Y, Jiao Z, Ding J, Li G-F (2020) How to handle delayed or missed doses: a population pharmacokinetic perspective. Eur J Drug Metab Pharmacokinet 45(2):163–172

Article  Google Scholar 

Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcelly Dekker, New York

Book  Google Scholar 

Felmlee MA, Morris ME, Mager DE. Mechanism-based pharmacodynamic modeling. In: Computational toxicology, pp 583–600. Springer, Berlin (2012)

Osterberg LG, Urquhart J, Blaschke TF (2010) Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther 88(4):457–459

Article  CAS  PubMed  Google Scholar 

Urquhart J (2002) The odds of the three nons when an aptly prescribed medicine isn’t working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol 54(2):212–220

Article  PubMed  PubMed Central  Google Scholar 

Levy G (1993) A pharmacokinetic perspective on medicament noncompliance. Clin Pharmacol Ther 54(3):242–244

Article  CAS  PubMed  Google Scholar 

Web app at https://seanlawley.shinyapps.io/OnOff/

Norris JR (1998) Markov chains. In: Statistical & probabilistic mathematics. Cambridge University Press, Cambridge

Yuval P, Wilhelm S, Boris S (2000) Sixty years of Bernoulli convolutions. In: Bandt C, Graf S, Zähle M (eds) Fractal geometry and stochastics II. Birkhäuser, Basel, pp 39–65

Google Scholar 

Solomyak B (1995) On the random series \(\sum \pm \lambda ^n\) (an erdos problem). Ann Math 142(3):611–625

Article  Google Scholar 

Escribano C, Sastre MA, Torrano E (2001) Moments of infinite convolutions of symmetric Bernoulli distributions. J Comput Appl Math 153(1):191–199, 2003. In: Proceedings of the 6th international symposium on orthogonal polynomials, special functions and their applications, Rome, Italy, 18–22

Tian-You H, Lau K-S (2008) Spectral property of the Bernoulli convolutions. Adv Math 219(2):554–567

Article  Google Scholar 

Kershner R, Wintner A (1935) On symmetric Bernoulli convolutions. Am J Math 57(3):541–548

Article  Google Scholar 

Jessen B, Wintner A (1935) Distribution functions and the Riemann zeta function. Trans Am Math Soc 38(1):48–88

Article  Google Scholar 

Wintner A (1935) On symmetric Bernoulli convolutions. Bull Am Math Soc 41:137–138

Article  Google Scholar 

Erdös P (1939) On a family of symmetric Bernoulli convolutions. Am J Math 61:974

Article  Google Scholar 

Lévy-Véhel P-E, Lévy-Véhel J (2013) Variability and singularity arising from poor compliance in a pharmacokinetic model I: the multi-IV case. J Pharmacokinet Pharmacodyn 40(1):15–39

Article  PubMed  Google Scholar 

Fermín LJ, Lévy-Véhel J (2017) Variability and singularity arising from poor compliance in a pharmacokinetic model II: the multi-oral case. J Math Biol 74(4):809–841

Article  PubMed  Google Scholar 

Counterman ED, Lawley SD (2021) What should patients do if they miss a dose of medication? A theoretical approach. J Pharmacokinet Pharmacodyn 48(6):873–892

Article  PubMed  Google Scholar 

Counterman ED, Lawley SD (2022) Designing drug regimens that mitigate nonadherence. Bull Math Biol 84(1):1–36

Article  Google Scholar 

Burnier M (2019) Is there a threshold for medication adherence? Lessons learnt from electronic monitoring of drug adherence. Front Pharmacol 9:1540

Article  PubMed  PubMed Central  Google Scholar 

Brian HR (1976) Compliance with therapeutic regimens, chapter A critical review of “determinants’’ of patient compliance with therapeutic regimens. Johns Hopkins University Press, Baltimore, pp 26–39

Google Scholar 

Radauceanu A, Virion J-M, Boivin J-M, Zannad F (2002) Time-effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. quinapril1. Fundam Clin Pharmacol 16(6):545–554

Article  CAS  PubMed  Google Scholar 

Vaur L, Bobrie G, Dutrey-Dupagne C, Dubroca I, Vaisse B, Bouvier d’Yvoire M, Elkik FE, Chatellier G, Menard J (1998) Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. Am J Hypertens 11(2):165–173

Article  CAS  PubMed  Google Scholar 

Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL (2010) Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 24(2):93–103

Article  CAS  PubMed  Google Scholar 

Yves Lacourciere and for the Candesartan/Losartan study investigators Asmar, Roland. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients*: a placebo-controlled, forced titration study. Am J Hypertens 12(12):1181–1187 (1999)

Johnson BF, Whelton A (1994) A study design for comparing the effects of missing daily dos